Houston, Texas–(Newsfile Corp. – March 20, 2020) – Infectious diseases are an unavoidable part of life.
To help combat such issues, doctors can turn to antiviral treatments, which fight infection by slowing a virus’ ability to reproduce and strengthening the body’s immune response.
Oftentimes, they’re use with issues stemming from influenza, HIV, and hepatitis among others.
Now, there’s also hope such treatments can be used to treat the coronavirus.
At the moment, “Doctors are still trying ‘desperately’ to find a proven treatment for the coronavirus – with most patients currently being given a mix of antiviral drugs typically used for HIV and malaria,” as reported by the New York Post.
Even President Trump has praised antiviral treatments in recent days. For example, he said he was “very excited” about chloroquine as a potential antiviral treatment for the virus. There are a lot of reasons why I think it could have a positive effect,” said the president,” as quoted by Barron’s. “It’s been out for years and we know it could be taken safely.”
The country of Georgia is even negotiating with Gilead to its antiviral drug, Remdesivir.
“Remdesivir, which was created by Gilead, has been very actively used against COVID-19 in China, together with other anti-virus medicines, as well as anti-HIV drugs. The Georgian government has requested Gilead provide the medicine and I believe that the request will be granted and we will have the medicine in reserve stock,” according to Agenda.
Rising incidences of such infections, rising healthcare costs, and the unfortunate development of life-threatening infections, such as COVID-19 are expected to help create a $71.48 billion anti-viral drug market by 2026, according to Reports and Data.
One of the Potential Beneficiaries is Yield Growth Corp.
Yield Growth just announced it will start R&D on plant-based topical products that can fight against or prevent infectious disease. The research will include a study of certain plant-based compounds for antimicrobial activity against pathogens for potential antiviral treatments.
Based on Yield Growth’s existing intellectual property and deep understanding of plant-based products, its current THC infused products, and anticipated future demand for antiviral therapeutics, Yield Growth has initiated a plant-based research and development program to examine antimicrobial effects of certain natural compounds.
If the results are promising, Yield Growth will pursue development of certain compounds into products for antiviral treatments.
“Our hearts and minds go out to everyone suffering from the recent viral outbreak of COVID-19 and we applaud those working on the front lines to treat and contain the virus,” says Penny White, Yield Growth CEO. “While we continue to market, develop and launch products through our existing brands, we are leveraging our experienced team to conduct research and develop products that can help fight against COVID-19 and other infectious diseases.”
In addition, Yield Growth, through its subsidiary Flourish Mushroom Labs, last month purchased an interest in pharmaceutical and contract research organization Translational Life Sciences Inc. which is in the early stages of conducting research and development into using restricted substances for therapeutic uses. Yield Growth is now expanding its research and development program into potential plant-based products to protect against infection.
“Herbs and essential oils have been used for centuries for their antiviral, antifungal, and antibacterial properties ” says Bhavna Solecki, Director of Product Research for Yield Growth. “Essential oils and other plant based ingredients may be a potential alternative to synthetic compounds because of the resistance that has been increasingly developed by pathogenic microorganisms. With the rapid spread of the COVID-19 worldwide pandemic, our research and development team is working wholeheartedly and consciously to provide natural solutions based on ancient plant pharmacology.”
For more information, visit the company’s website at https://yieldgrowth.com.
MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53645